Northern Trust Corp Buys 123,205 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Northern Trust Corp grew its holdings in MiMedx Group, Inc. (NASDAQ:MDXG) by 11.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,199,970 shares of the company’s stock after buying an additional 123,205 shares during the quarter. Northern Trust Corp owned approximately 0.82% of MiMedx Group worth $11,544,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Cannell Capital LLC increased its stake in shares of MiMedx Group by 1.1% in the fourth quarter. Cannell Capital LLC now owns 3,639,545 shares of the company’s stock valued at $35,012,000 after buying an additional 40,235 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of MiMedx Group by 18.4% in the fourth quarter. Renaissance Technologies LLC now owns 1,804,557 shares of the company’s stock valued at $17,360,000 after buying an additional 280,327 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of MiMedx Group by 15.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,802,364 shares of the company’s stock valued at $17,338,000 after buying an additional 238,075 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of MiMedx Group by 133.1% in the fourth quarter. JPMorgan Chase & Co. now owns 693,106 shares of the company’s stock valued at $6,668,000 after buying an additional 395,739 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of MiMedx Group by 0.7% in the fourth quarter. Bank of New York Mellon Corp now owns 504,007 shares of the company’s stock valued at $4,849,000 after buying an additional 3,300 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at MiMedx Group

In other MiMedx Group news, CEO Joseph H. Capper acquired 200,000 shares of the business’s stock in a transaction dated Friday, May 2nd. The shares were acquired at an average price of $6.34 per share, for a total transaction of $1,268,000.00. Following the acquisition, the chief executive officer now directly owns 529,530 shares of the company’s stock, valued at approximately $3,357,220.20. This trade represents a 60.69% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO William Frank Iv Hulse sold 54,596 shares of MiMedx Group stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $430,762.44. Following the transaction, the chief accounting officer now owns 440,178 shares in the company, valued at $3,473,004.42. This trade represents a 11.03% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 144,018 shares of company stock worth $1,130,312. 1.70% of the stock is currently owned by company insiders.

MiMedx Group Price Performance

Shares of MDXG stock opened at $7.05 on Friday. The stock has a 50-day moving average price of $7.19 and a 200 day moving average price of $8.16. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of 12.82 and a beta of 1.85. MiMedx Group, Inc. has a 12 month low of $5.47 and a 12 month high of $10.14.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Wednesday, April 30th. The company reported $0.06 EPS for the quarter, hitting analysts’ consensus estimates of $0.06. The firm had revenue of $88.21 million during the quarter, compared to analyst estimates of $86.32 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. Research analysts expect that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Analyst Upgrades and Downgrades

MDXG has been the subject of a number of research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 target price on shares of MiMedx Group in a research note on Thursday, February 27th. StockNews.com lowered MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 9th.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.